Bioxyne hits record quarterly revenue by Adam Sheldon January 28, 2026January 28, 2026 Brisbane manufacturer Bioxyne delivered record quarterly revenue of A$17.2 million in Q2 FY26, a 21% increase […]
Bioxyne enters Central American markets with pastille supply deal by Steve Jones December 12, 2025December 12, 2025
‘Not a revenue grab’: Curaleaf International CEO maps out Australian expansion plan by Adam Sheldon November 27, 2025December 2, 2025
News in brief: Legalise Cannabis ramps up criticism of Victorian government; MCA launches desktop guide for clinicians; Bioxyne secures A$1.7m for UK GMP facility by Adam Sheldon November 17, 2025February 21, 2026
News in brief: Cann completes NAB settlement; Bioxyne releases GMP-certified MDMA capsules by Adam Sheldon November 11, 2025February 21, 2026
Breathe Life Sciences launches Curaleaf medical inhalation device by Adam Sheldon November 3, 2025November 3, 2025
Record revenue for Bioxyne but cash deficit rises after flower investment by Steve Jones October 30, 2025November 3, 2025
Cannabis executive salaries: who earned what in FY25 by Adam Sheldon October 22, 2025October 22, 2025
News in brief: The Entourage Effect named AFR innovation finalist; Bioxyne lists in Germany; Nimbin to host medical cannabis symposium by Steve Jones October 13, 2025February 21, 2026
‘It’s super exciting’ – Breathe Life Sciences secures ARTG listings for Dr Watson range by Adam Sheldon October 9, 2025October 13, 2025
